"The US ADHD medication shortage continues to impact millions of Americans, with many unable to access essential stimulant medications like Adderall and Vyvanse. In this eye-opening episode, we dive deep into how DEA's restrictive production quotas are creating a nationwide healthcare crisis, particularly affecting the growing population of adults with ADHD.

Discover why experts are calling the DEA's quota system outdated and inflexible, how COVID-19 changed the landscape of ADHD diagnoses, and what needs to change to ensure patients can access their vital medications. From understanding the complexities of adult ADHD treatment to exposing the systematic failures leading to this shortage, we unpack the real human impact of bureaucratic decisions made years in advance. Join us as we explore potential solutions and the urgent need for reform in America's controlled substance regulations."